Adriamycin distribution in plasma and blood cells of cancer patients with altered hematocrit

E. Piazza, M. Broggini, A. Trabattoni, N. Natale, A. Libretti, M. G. Donelli

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Adriamycin (AM) distribution in the cellular and plasma components of blood has been investigated in cancer patients with hematocrit values ranging from 23 to 49 after i.v. drug doses (40-70 mg/m2). AM was measured by a fluorimetric technique in total blood, plasma and blood cells. Blood levels were found to be related to the dose, and when the number of blood cells per milliliter was low, a smaller amount of AM was found in the cell fraction and a larger amount was found in the plasma fraction. A further result of these studies was that, as already shown in Walker-bearing rats, AM accumulated to a marked extent in blood cells, particularly platelets, as expressed by the drug concentration per unit volume, and persisted longer in white blood cells and platelets than red cells, suggesting that the various cells have different roles in transport, storage or metabolism of the compound.

Original languageEnglish
Pages (from-to)1089-1096
Number of pages8
JournalEuropean Journal of Cancer (1965)
Volume17
Issue number10
DOIs
Publication statusPublished - 1981

Fingerprint

Plasma Cells
Hematocrit
Doxorubicin
Blood Cells
Neoplasms
Blood Platelets
Walkers
Blood Cell Count
Pharmaceutical Preparations
Leukocytes

ASJC Scopus subject areas

  • Oncology

Cite this

Adriamycin distribution in plasma and blood cells of cancer patients with altered hematocrit. / Piazza, E.; Broggini, M.; Trabattoni, A.; Natale, N.; Libretti, A.; Donelli, M. G.

In: European Journal of Cancer (1965), Vol. 17, No. 10, 1981, p. 1089-1096.

Research output: Contribution to journalArticle

Piazza, E. ; Broggini, M. ; Trabattoni, A. ; Natale, N. ; Libretti, A. ; Donelli, M. G. / Adriamycin distribution in plasma and blood cells of cancer patients with altered hematocrit. In: European Journal of Cancer (1965). 1981 ; Vol. 17, No. 10. pp. 1089-1096.
@article{04314585c50e45f486d3c7734817cfaf,
title = "Adriamycin distribution in plasma and blood cells of cancer patients with altered hematocrit",
abstract = "Adriamycin (AM) distribution in the cellular and plasma components of blood has been investigated in cancer patients with hematocrit values ranging from 23 to 49 after i.v. drug doses (40-70 mg/m2). AM was measured by a fluorimetric technique in total blood, plasma and blood cells. Blood levels were found to be related to the dose, and when the number of blood cells per milliliter was low, a smaller amount of AM was found in the cell fraction and a larger amount was found in the plasma fraction. A further result of these studies was that, as already shown in Walker-bearing rats, AM accumulated to a marked extent in blood cells, particularly platelets, as expressed by the drug concentration per unit volume, and persisted longer in white blood cells and platelets than red cells, suggesting that the various cells have different roles in transport, storage or metabolism of the compound.",
author = "E. Piazza and M. Broggini and A. Trabattoni and N. Natale and A. Libretti and Donelli, {M. G.}",
year = "1981",
doi = "10.1016/0014-2964(81)90293-0",
language = "English",
volume = "17",
pages = "1089--1096",
journal = "European Journal of Cancer",
issn = "0014-2964",
publisher = "Elsevier Ltd",
number = "10",

}

TY - JOUR

T1 - Adriamycin distribution in plasma and blood cells of cancer patients with altered hematocrit

AU - Piazza, E.

AU - Broggini, M.

AU - Trabattoni, A.

AU - Natale, N.

AU - Libretti, A.

AU - Donelli, M. G.

PY - 1981

Y1 - 1981

N2 - Adriamycin (AM) distribution in the cellular and plasma components of blood has been investigated in cancer patients with hematocrit values ranging from 23 to 49 after i.v. drug doses (40-70 mg/m2). AM was measured by a fluorimetric technique in total blood, plasma and blood cells. Blood levels were found to be related to the dose, and when the number of blood cells per milliliter was low, a smaller amount of AM was found in the cell fraction and a larger amount was found in the plasma fraction. A further result of these studies was that, as already shown in Walker-bearing rats, AM accumulated to a marked extent in blood cells, particularly platelets, as expressed by the drug concentration per unit volume, and persisted longer in white blood cells and platelets than red cells, suggesting that the various cells have different roles in transport, storage or metabolism of the compound.

AB - Adriamycin (AM) distribution in the cellular and plasma components of blood has been investigated in cancer patients with hematocrit values ranging from 23 to 49 after i.v. drug doses (40-70 mg/m2). AM was measured by a fluorimetric technique in total blood, plasma and blood cells. Blood levels were found to be related to the dose, and when the number of blood cells per milliliter was low, a smaller amount of AM was found in the cell fraction and a larger amount was found in the plasma fraction. A further result of these studies was that, as already shown in Walker-bearing rats, AM accumulated to a marked extent in blood cells, particularly platelets, as expressed by the drug concentration per unit volume, and persisted longer in white blood cells and platelets than red cells, suggesting that the various cells have different roles in transport, storage or metabolism of the compound.

UR - http://www.scopus.com/inward/record.url?scp=0019416260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019416260&partnerID=8YFLogxK

U2 - 10.1016/0014-2964(81)90293-0

DO - 10.1016/0014-2964(81)90293-0

M3 - Article

C2 - 7200018

AN - SCOPUS:0019416260

VL - 17

SP - 1089

EP - 1096

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0014-2964

IS - 10

ER -